$420,000.00 in Sales Expected for Syros Pharmaceuticals Inc (NASDAQ:SYRS) This Quarter

Equities research analysts forecast that Syros Pharmaceuticals Inc (NASDAQ:SYRS) will post $420,000.00 in sales for the current fiscal quarter, Zacks reports. Four analysts have issued estimates for Syros Pharmaceuticals’ earnings, with estimates ranging from $400,000.00 to $450,000.00. Syros Pharmaceuticals reported sales of $380,000.00 during the same quarter last year, which indicates a positive year-over-year growth rate of 10.5%. The firm is expected to report its next quarterly earnings report on Tuesday, August 6th.

According to Zacks, analysts expect that Syros Pharmaceuticals will report full-year sales of $1.72 million for the current financial year, with estimates ranging from $1.65 million to $1.80 million. For the next financial year, analysts expect that the company will report sales of $1.87 million, with estimates ranging from $1.60 million to $2.00 million. Zacks’ sales calculations are a mean average based on a survey of research firms that follow Syros Pharmaceuticals.

Syros Pharmaceuticals (NASDAQ:SYRS) last announced its earnings results on Wednesday, May 1st. The company reported ($0.49) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.57) by $0.08. The firm had revenue of $0.45 million for the quarter, compared to analyst estimates of $0.42 million. Syros Pharmaceuticals had a negative return on equity of 74.28% and a negative net margin of 3,012.04%.

A number of brokerages have weighed in on SYRS. ValuEngine upgraded Syros Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday. BidaskClub upgraded Syros Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday, June 20th. Zacks Investment Research upgraded Syros Pharmaceuticals from a “hold” rating to a “buy” rating and set a $7.25 price objective on the stock in a report on Thursday, May 9th. HC Wainwright restated a “neutral” rating on shares of Syros Pharmaceuticals in a report on Thursday, May 2nd. Finally, Wedbush restated an “outperform” rating and issued a $13.00 price objective on shares of Syros Pharmaceuticals in a report on Thursday, April 25th. Three investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus price target of $15.66.

In related news, Director Srinivas Akkaraju bought 533,332 shares of the business’s stock in a transaction on Tuesday, April 9th. The stock was acquired at an average cost of $7.50 per share, with a total value of $3,999,990.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 14.80% of the stock is owned by company insiders.

Institutional investors and hedge funds have recently modified their holdings of the business. BNP Paribas Arbitrage SA acquired a new stake in shares of Syros Pharmaceuticals in the 1st quarter worth $48,000. Bank of America Corp DE increased its stake in shares of Syros Pharmaceuticals by 205.9% in the 4th quarter. Bank of America Corp DE now owns 17,400 shares of the company’s stock worth $98,000 after acquiring an additional 11,711 shares during the last quarter. Rhumbline Advisers increased its stake in shares of Syros Pharmaceuticals by 51.4% in the 4th quarter. Rhumbline Advisers now owns 32,406 shares of the company’s stock worth $181,000 after acquiring an additional 10,995 shares during the last quarter. Los Angeles Capital Management & Equity Research Inc. increased its stake in shares of Syros Pharmaceuticals by 8.3% in the 1st quarter. Los Angeles Capital Management & Equity Research Inc. now owns 40,380 shares of the company’s stock worth $369,000 after acquiring an additional 3,100 shares during the last quarter. Finally, Bank of New York Mellon Corp increased its stake in shares of Syros Pharmaceuticals by 10.0% in the 3rd quarter. Bank of New York Mellon Corp now owns 77,654 shares of the company’s stock worth $925,000 after acquiring an additional 7,062 shares during the last quarter. 56.16% of the stock is owned by institutional investors and hedge funds.

Shares of SYRS stock opened at $7.52 on Wednesday. The company has a fifty day moving average price of $6.46. The company has a quick ratio of 5.19, a current ratio of 5.19 and a debt-to-equity ratio of 0.02. The stock has a market cap of $283.43 million, a price-to-earnings ratio of -3.94 and a beta of 1.27. Syros Pharmaceuticals has a fifty-two week low of $5.17 and a fifty-two week high of $13.18.

About Syros Pharmaceuticals

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for cancer and monogenic diseases, and building a pipeline of gene control medicines. Its lead product candidates include SY-1425, a selective retinoic acid receptor alpha agonist, which is in a Phase II clinical trial for genomically defined subsets of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome; SY-1365, a selective cyclin-dependent kinase 7 (CDK7) inhibitor, which is in a Phase I clinical trial that is used for treating patients with solid tumors and blood cancers, including ovarian and breast cancer; and SY-5609, a CDK7 inhibitor, which is in preclinical studies to treat oncology patients.

Further Reading: What is the Fibonacci sequence?

Get a free copy of the Zacks research report on Syros Pharmaceuticals (SYRS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Syros Pharmaceuticals (NASDAQ:SYRS)

Receive News & Ratings for Syros Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.